January 24, 2017
â¨The London School of Economics and Political Science (LSE) and Boston Consulting Group (BCG) have partnered with leading big pharma companies to create The LSE Health Market Access Academy, which aims "to train top performers from all of the world’s leading pharma companies, giving them advanced knowledge and strategies in the field of market access".
AbbVie, AstraZeneca, Amgen, Bayer, Eli Lilly, Janssen, Merck EMD, Pfizer, Roche, Sanofi, Takeda and UCB have joined the initiative to create "what will be the first collaborative market access management development program".
The weeklong program will consist of five modules that aim to deepen participants’ market access knowledge, exploring areas such as understanding access drivers and barriers, defining an integrated evidence package, creating a receptive access environment, optimizing access and value, and managing access strategy.
The first two waves of the LSE Health Market Access Academy will take place March 27-31 and September 11-15, 2017 in London, with future international delivery dates to be announced in 2018.
LSE Health encourages applications through their website, www.LSEMarketAccess.com.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.